#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Chronic granulomatous disease Malignant glioma Congenital generalised lipodystrophy Endometrial cancer Anal cancer recurrent Follicle centre lymphoma follicular grade I, II – III Systemic sclerosis pulmonary Ocular lymphoma Choroidal dystrophy Gastric cancer Ureteric cancer Thrombocytopenia Adenocarcinoma pancreas Chordoma Fabry's disease More trials…

    Learn about Rare Diseases

    Chordoma – Basic Information Amyotrophic lateral sclerosis Activated PI3 kinase delta syndrome – Diagnostics Angiosarcoma non-metastatic Antisynthetase syndrome – Basic Information Rhabdomyosarcoma recurrent – Trials in Disease Cytokine release syndrome – Diagnostics Short-bowel syndrome – Trials in Disease Angiosarcoma recurrent – Treatment Primary hyperoxaluria – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Bjt-778 Nazartinib Sodium Oxybate Corticosteroids, Plain Amb-05X Pegaspargase Gen3017 IMMUNOSTEM Crovalimab Etavopivat NORELGESTROMIN Paclitaxel Obaluronate Mavacamten Gsk4004280 Tegoprubart PIPOTIAZINE Cetrelimab Methylphenidate Hydrochloride Cytarabine Futibatinib More therapies…

    Learn about Your Condition

    Prostate cancer recurrent Vaginal cancer Desmoid tumour Tendon injury Diabetic ketoacidosis Notalgia paraesthetica Neuromuscular scoliosis Malignant lymphoid neoplasm Traumatic pain Metastatic neoplasm Immune-mediated myositis Cognitive disorder Schizophrenia Renal cancer recurrent Large cell lung cancer stage 0 More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Breast cancer metastatic

  • Study on Adding Elacestrant to Olaparib for Patients with HR-Positive, HER2-Negative Advanced Breast Cancer with gBRCA1/2 Mutations

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Elacestrant Dihydrochloride
    • Olaparib
    Germany

  • Study of Palbociclib and Fulvestrant for Women with Advanced Breast Cancer After Previous CDK4/6 Inhibitor and Hormonal Therapy

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    Investigated Drugs:
    • Palbociclib
    Italy

  • Study to Determine the Best Dose of Zongertinib with Trastuzumab Deruxtecan or Trastuzumab Emtansine for Patients with Advanced HER2+ Metastatic Cancer

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Calcium Folinate
    • Capecitabine
    • Fluorouracil
    Belgium France Germany Italy Spain

  • Study on the Effectiveness and Safety of Tocilizumab and Drug Combination for Patients with Metastatic Breast Cancer

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    Investigated Drugs:
    • Metformin
    • ATIRMOCICLIB
    • Empagliflozin
    France Germany Spain

  • Study on the Effectiveness of Trastuzumab Deruxtecan in Patients with HER2-Positive Oligometastatic Breast Cancer

    Recruiting

    2 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • HER2 positive breast cancer
    Investigated Drugs:
    • Trastuzumab Deruxtecan
    France Italy The Netherlands Spain Sweden

  • Study on Lasofoxifene, Fulvestrant, and Abemaciclib for Advanced Breast Cancer in Women and Men with ESR1 Mutation

    Recruiting

    3 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    Investigated Drugs:
    • Lasofoxifene
    • Abemaciclib
    • Fulvestrant
    Belgium France Germany Hungary Italy Poland +2
Previous Page
1 2 3 4 5 6 … 14
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!